SCYNEXIS (NASDAQ:SCYX) Stock Rating Upgraded by StockNews.com

SCYNEXIS (NASDAQ:SCYX) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a report released on Friday.

SCYNEXIS Stock Down 1.5 %

Shares of SCYX opened at $1.31 on Friday. The stock has a market capitalization of $49.71 million, a P/E ratio of -1.77 and a beta of 1.50. The firm has a fifty day simple moving average of $1.45 and a two-hundred day simple moving average of $1.80. SCYNEXIS has a twelve month low of $1.26 and a twelve month high of $3.07.

SCYNEXIS (NASDAQ:SCYX) last posted its earnings results on Thursday, August 8th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.11). SCYNEXIS had a negative return on equity of 63.67% and a negative net margin of 425.41%. The company had revenue of $0.74 million during the quarter. Sell-side analysts expect that SCYNEXIS will post -0.68 EPS for the current fiscal year.

Insider Transactions at SCYNEXIS

In related news, CEO Gonzalez David Angulo bought 20,000 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was purchased at an average cost of $1.37 per share, with a total value of $27,400.00. Following the transaction, the chief executive officer now owns 507,871 shares in the company, valued at approximately $695,783.27. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 2.85% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Empowered Funds LLC increased its stake in shares of SCYNEXIS by 8.1% in the 1st quarter. Empowered Funds LLC now owns 88,414 shares of the company’s stock worth $130,000 after acquiring an additional 6,650 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of SCYNEXIS by 5.4% in the 1st quarter. Acadian Asset Management LLC now owns 421,083 shares of the company’s stock worth $618,000 after acquiring an additional 21,700 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of SCYNEXIS by 8.3% in the 1st quarter. Vanguard Group Inc. now owns 1,687,670 shares of the company’s stock worth $2,481,000 after acquiring an additional 129,153 shares in the last quarter. 54.37% of the stock is currently owned by institutional investors.

SCYNEXIS Company Profile

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.